DAY101 vs. Standard of Care Chemotherapy in Pediatric Participants With Low-Grade Glioma Requiring First-Line Systemic Therapy (LOGGIC/FIREFLY-2)

Clinical trial NCT05566795 · ACTIVE_NOT_RECRUITING

Trial details

NCT number: NCT05566795
Sponsor: Day One Biopharmaceuticals, Inc.
Status: ACTIVE_NOT_RECRUITING
Phase: Phase 3
Study type: INTERVENTIONAL

Low-grade Glioma Rapidly Accelerated Fibrosarcoma (RAF) Altered Glioma Pediatric Low-grade Glioma

Start date: 2023-02-27
Primary completion: 2027-06-01
Enrollment: 418

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.